Effect of environmental enrichment on methylphenidate-induced locomotion and dopamine transporter dynamics
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Rats raised in an enriched condition (EC) are less sensitive to the locomotor effects of stimulant drugs than rats raised in an impoverished condition (IC). Methylphenidate (MPD), a primary pharmacotherapy for attention-deficit/hyperactivity disorder, has abuse potential. This study determined whether environmental enrichment differentially altered the effects of MPD on locomotor activity and dopamine (DA) transporter (DAT) function. Acute and repeated MPD (3 or 10 mg/kg, s.c.) increased locomotion in EC, IC and social condition (SC) rats; however, EC rats showed a blunted response to repeated MPD (3 mg/kg). The maximal velocity (Vmax) of [3H]DA uptake in the presence of the combination of phorbol 12-myristate 13-acetate, a protein kinase C (PKC) activator and okadaic acid, a protein phosphatase inhibitor was decreased in EC and IC rats by 68% and 40%, respectively, indicating that DAT in prefrontal cortex (PFC) is more sensitive to PKC-mediated down-regulation in EC rats. Acute MPD (10 mg/kg) administration decreased the Vmax of [3H]DA uptake in PFC and striatum in EC rats, but not in IC rats. Furthermore, [3H]WIN 35,428 binding density was decreased in PFC of EC and IC rats, and in striatum of EC rats given repeated MPD (10 mg/kg). These results demonstrate that environmental enrichment modulates DAT dynamics in PFC. However, since the change in DAT function was observed only following the high dose of MPH (10 mg/kg), the attenuated locomotor response to repeated MPD (3 mg/kg) in EC rats is not likely due to a specific DAT alteration in the brain regions examined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective
Bechara, A. (2005) · Nature Neuroscience · doi:10.1038/nn1584 · Cited by 2,149 · cited 1×
“In addition to drug abuse vulnerability, environmental conditions also can modulate individual differences in impulsivity, which has been linked to drug abuse [9–15].”
BackgroundNeuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes
Castellanos, F. X., & Tannock, R. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn896 · Cited by 1,827 · cited 2×
“This region is also known to play a prominent role in the pathology of ADHD, and is an important mediator of the therapeutic actions of MPD [34–37].”
BackgroundGenetics of Mouse Behavior: Interactions with Laboratory Environment
Crabbe, J. C., Wahlsten, D., & Dudek, B. C. (1999) · Science · doi:10.1126/science.284.5420.1670 · Cited by 1,666
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939 · cited 1×
“Since GBR12935 is a selective DAT inhibitor [47,62,63], whereas MPD inhibits both DAT and NET [64–66], the discrepant findings obtained with MPD in the current report may be due to, at least in part, to the involvement of both transporters [64–66].”
ResultSolanto, M. V. (1998) · Behavioural Brain Research · doi:10.1016/s0166-4328(97)00175-7 · Cited by 677
Drug addiction: the neurobiology of disrupted self-control
Baler, R. D., & Volkow, N. D. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.10.005 · Cited by 640 · cited 1×
“In addition to drug abuse vulnerability, environmental conditions also can modulate individual differences in impulsivity, which has been linked to drug abuse [9–15].”
BackgroundBerridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617 · cited 2×
“In accord with this notion, low doses of MPD are known to preferentially increase both DA and NE efflux in PFC compared to limbic structures [43].”
BackgroundVariables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Volkow, N. D., & Swanson, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.11.1909 · Cited by 475 · cited 1×
“MPD produces effects typical of psychostimulant drugs, including abuse liability [23,24].”
BackgroundDiergaarde, L., Pattij, T., Poortvliet, I., Hogenboom, F., de Vries, W., Schoffelmeer, A. N. M., & De Vries, T. J. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.011 · Cited by 391 · cited 1×
“However, impulsivity is a multifaceted construct [13,14,16], and it is possible that environmental enrichment may alter distinct aspects of impulsivity differently.”
BackgroundPerry, J. L., Larson, E. B., German, J. P., Madden, G. J., & Carroll, M. E. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1994-4 · Cited by 388 · cited 1×
“In addition to drug abuse vulnerability, environmental conditions also can modulate individual differences in impulsivity, which has been linked to drug abuse [9–15].”
BackgroundThe neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
Perry, J. L., Joseph, J. E., Jiang, Y., Zimmerman, R. S., Kelly, T. H., Darna, M., Huettl, P., Dwoskin, L. P., & Bardo, M. T. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2010.09.001 · Cited by 180 · cited 2×
“However, impulsivity is a multifaceted construct [13,14,16], and it is possible that environmental enrichment may alter distinct aspects of impulsivity differently.”
BackgroundSelf-citationRubia, K., Halari, R., Cubillo, A., Mohammad, A., Scott, S., & Brammer, M. (2010) · Human Brain Mapping · doi:10.1002/hbm.20975 · Cited by 153 · cited 2×
“This region is also known to play a prominent role in the pathology of ADHD, and is an important mediator of the therapeutic actions of MPD [34–37].”
BackgroundZhu, J., & Reith, M. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708786927877 · Cited by 140 · cited 2×
“While the exact biochemical mechanisms underlying these differences are not clear, the dynamic regulation of DAT function is under the control of complex processes involving phosphorylation, proteinprotein interaction, substrate pretreatment, and interactions with presynaptic receptors [47].”
BackgroundResultSelf-citationEaston, N., Steward, C., Marshall, F., Fone, K., & Marsden, C. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.07.035 · Cited by 101
Psychopharmacology: concepts and opinions about the use of stimulant medications
Swanson, J. M., & Volkow, N. D. (2009) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2008.02062.x · Cited by 78 · cited 11×
“Overall, individuals with attention-deficit hyperactivity disorder (ADHD) tend to show greater levels of impulsivity, which are typically reduced by administration of stimulant medications [17–19]; specifically, it has been argued that deficient response inhibition is a particularly important aspect of impulsivity tha…”
BackgroundInfluential
Cited by
Individual Differences and Social Influences on the Neurobehavioral Pharmacology of Abused Drugs
Bardo, M. T., Neisewander, J. L., & Kelly, T. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005124 · Cited by 167
“, 2004), an effect that involves protein kinase C (Wooters et al., 2011).”
BackgroundSelf-citationOpioid addiction: who are your real friends?
Eitan, S., Emery, M. A., Bates, M. L. S., & Horrax, C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.05.017 · Cited by 42
Gill, K. E., Beveridge, T. J. R., Smith, H. R., & Porrino, L. J. (2013) · Brain Research · doi:10.1016/j.brainres.2013.06.021 · Cited by 30
Metadata
- Authors
- Wooters, T. E., Bardo, M. T., Dwoskin, L. P., Midde, N. M., Gomez, A. M., Mactutus, C. F., Booze, R. M., & Zhu, J.
- Venue
- Behavioural Brain Research
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 219
- Issue
- 1
- Pages
- 98-107
- ISSN
- 0166-4328 (ISSN-L)
- OpenAlex
- W2133711068
- Cited by
- 35
- References
- 16
- FWCI
- 1.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.